Wegovy & Sight Loss: Weight Loss Drug Eye Stroke Risk Analyzed

A new study published in the British Journal of Ophthalmology suggests that Wegovy, the higher-dose version of the weight loss drug semaglutide, may be associated with a significantly increased risk of developing a rare eye condition that can lead to sudden vision loss. The research, which analyzed reports of adverse side effects, found that individuals taking Wegovy for weight management had a fivefold greater chance of developing non-arteritic anterior ischemic optic neuropathy (Naion) compared to those using Ozempic, a semaglutide-based medication for type 2 diabetes.

Understanding ‘Eye Strokes’ and Semaglutide

Naion, often referred to as an “eye stroke,” occurs when blood flow to the optic nerve is disrupted, potentially causing sudden and permanent vision loss. While relatively uncommon, affecting around one in 10,000 people taking semaglutide, the study highlights a “potential dose-dependent safety concern,” meaning the risk may increase with higher dosages of the drug. Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA), a class of medications that likewise includes tirzepatide (Mounjaro). These drugs operate by reducing blood sugar levels, slowing digestion, and suppressing appetite, and have shown promise in reducing the risk of heart attack and other health benefits. The Guardian reports on the findings.

Wegovy, Ozempic, and Rybelsus – all manufactured by Novo Nordisk – contain semaglutide but differ in their dosages and formulations. The study’s findings have prompted increased scrutiny of the potential ocular side effects associated with these medications, particularly Wegovy due to its higher dose.

What the Study Examined and Its Limitations

The research involved an analysis of adverse event reports, rather than a randomized controlled trial. This means the study can identify an association between Wegovy and Naion, but it cannot definitively prove that the drug causes the condition. It’s possible that other factors, such as pre-existing conditions or lifestyle choices, could contribute to the risk. Dr. Edward Margolin, an ophthalmologist at the University of Toronto and one of the study’s authors, suggests that Naion is “a real side-effect” of semaglutide, and that faster weight loss may further “increase the risk.”

The study also noted a difference in risk based on gender, with men experiencing a three times greater risk of Naion compared to women. The reasons for this disparity are currently unclear and require further investigation.

Guidance from Healthcare Authorities

In response to growing concerns, the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK issued a drug safety update on February 5, 2026, advising healthcare professionals to urgently refer patients reporting sudden vision loss while on semaglutide treatment for ophthalmological examination. The guidance emphasizes the importance of considering semaglutide utilize even in patients whose medical history doesn’t explicitly list the medication, as privately prescribed versions may not be recorded. Healthcare professionals are also advised to discontinue semaglutide treatment if Naion is confirmed and to inform new or existing patients about the potential risk of sudden vision loss, urging them to seek immediate medical attention if they experience any changes in their eyesight.

What Does This Mean for Patients?

For individuals currently taking Wegovy, Ozempic, or Rybelsus, it’s crucial to be aware of the potential risk of Naion and to promptly report any sudden changes in vision to their healthcare provider. Symptoms of Naion typically include sudden, painless vision loss in one eye, often described as blurring or cloudiness. It’s important to remember that Naion is rare, and the vast majority of people taking these medications will not experience this side effect. However, vigilance and early detection are key to minimizing potential vision loss.

The findings do not suggest that people should stop taking these medications without consulting their doctor. The benefits of these drugs for weight management and diabetes control may outweigh the risks for many individuals. A thorough discussion with a qualified clinician is essential to assess individual risk factors and make informed decisions about treatment.

Distinguishing Absolute vs. Relative Risk

The study reports a fivefold greater risk of Naion with Wegovy compared to Ozempic. This is a relative risk increase. It’s important to understand the absolute risk to put this into perspective. While a fivefold increase sounds alarming, the baseline risk of Naion is very low. Even a fivefold increase still represents a modest absolute risk. For example, if the baseline risk with Ozempic is one in 10,000, a fivefold increase would raise the risk to five in 10,000 – still a rare event. Medpage Today provides further context on the study’s findings.

The Ongoing Process of Drug Safety Surveillance

The identification of this potential risk highlights the importance of ongoing drug safety surveillance. Regulatory agencies like the MHRA and the U.S. Food and Drug Administration (FDA) continuously monitor adverse event reports to identify potential safety signals. When a potential signal is detected, further investigation is conducted to determine whether there is a causal link between the drug and the adverse event. This process may involve additional studies, data analysis, and updates to prescribing information.

What to Expect in the Coming Months

Several steps are likely to follow this initial study. Researchers will likely conduct further investigations to confirm the association between Wegovy and Naion, explore the underlying mechanisms, and identify potential risk factors. Healthcare professionals will be kept informed of any new developments through drug safety updates and professional guidelines. Patients are encouraged to report any suspected adverse drug reactions, including vision changes, through a Yellow Card scheme (in the UK) or similar reporting systems in other countries. The MHRA and other regulatory bodies will continue to monitor the safety of semaglutide and may issue further guidance as needed.